183: The effect of 17 alpha-hydroxyprogesterone caproate (17OHPC) on neonatal outcomes in infants delivering between 32-40 weeks

Abstract

ObjectiveTo compare neonatal outcomes between infants exposed to 17OHPC and those not exposed.Study DesignA retrospective examination of data from women enrolled for outpatient perinatal services between 1/01/2005 and 3/01/2009 identified deliveries at 32-40.9 weeks (w) gestational age at delivery (GAD) of live-born, singletons without anomalies. Each infant record was labeled as to if the mother had received at least 5 17OHPC injections during pregnancy (Y/N). Infants from women with indicated delivery due to maternal medical or fetal complications, or if the mother received <5 doses of 17 OHPC were excluded. Data were compared between 17OHPC exposed and non-exposed infants within each GAD group (32-33.9w, 34-35.9w, 36-37.9w, 38-40.9w) using Pearson′s chi-square and Mann-Whitney U test statistics.ResultsOverall, 13, 580 infants were studied: 4425 (32.6%) were exposed to 17OHPC and 9155 (67.4%) had no exposure. No significant differences were found in rates of low birth weight, macrosomia, respiratory problems, need for assisted ventilation, hypoglycemia, jaundice, or neonatal death for 17OHPC exposed vs. non-exposed infants within any GAD group, all p>0.05. Infants exposed to 17OHPC with GAD between 36-37.9 weeks had lower rates of NICU admission than those not exposed (10.0% vs. 12.7%, p=0.022).ConclusionWeekly administration of 17OHPC for prevention of preterm delivery does not appear to effect short-term neonatal outcomes among pregnancies after 32 weeks gestation. ObjectiveTo compare neonatal outcomes between infants exposed to 17OHPC and those not exposed. To compare neonatal outcomes between infants exposed to 17OHPC and those not exposed. Study DesignA retrospective examination of data from women enrolled for outpatient perinatal services between 1/01/2005 and 3/01/2009 identified deliveries at 32-40.9 weeks (w) gestational age at delivery (GAD) of live-born, singletons without anomalies. Each infant record was labeled as to if the mother had received at least 5 17OHPC injections during pregnancy (Y/N). Infants from women with indicated delivery due to maternal medical or fetal complications, or if the mother received <5 doses of 17 OHPC were excluded. Data were compared between 17OHPC exposed and non-exposed infants within each GAD group (32-33.9w, 34-35.9w, 36-37.9w, 38-40.9w) using Pearson′s chi-square and Mann-Whitney U test statistics. A retrospective examination of data from women enrolled for outpatient perinatal services between 1/01/2005 and 3/01/2009 identified deliveries at 32-40.9 weeks (w) gestational age at delivery (GAD) of live-born, singletons without anomalies. Each infant record was labeled as to if the mother had received at least 5 17OHPC injections during pregnancy (Y/N). Infants from women with indicated delivery due to maternal medical or fetal complications, or if the mother received <5 doses of 17 OHPC were excluded. Data were compared between 17OHPC exposed and non-exposed infants within each GAD group (32-33.9w, 34-35.9w, 36-37.9w, 38-40.9w) using Pearson′s chi-square and Mann-Whitney U test statistics. ResultsOverall, 13, 580 infants were studied: 4425 (32.6%) were exposed to 17OHPC and 9155 (67.4%) had no exposure. No significant differences were found in rates of low birth weight, macrosomia, respiratory problems, need for assisted ventilation, hypoglycemia, jaundice, or neonatal death for 17OHPC exposed vs. non-exposed infants within any GAD group, all p>0.05. Infants exposed to 17OHPC with GAD between 36-37.9 weeks had lower rates of NICU admission than those not exposed (10.0% vs. 12.7%, p=0.022). Overall, 13, 580 infants were studied: 4425 (32.6%) were exposed to 17OHPC and 9155 (67.4%) had no exposure. No significant differences were found in rates of low birth weight, macrosomia, respiratory problems, need for assisted ventilation, hypoglycemia, jaundice, or neonatal death for 17OHPC exposed vs. non-exposed infants within any GAD group, all p>0.05. Infants exposed to 17OHPC with GAD between 36-37.9 weeks had lower rates of NICU admission than those not exposed (10.0% vs. 12.7%, p=0.022). ConclusionWeekly administration of 17OHPC for prevention of preterm delivery does not appear to effect short-term neonatal outcomes among pregnancies after 32 weeks gestation. Weekly administration of 17OHPC for prevention of preterm delivery does not appear to effect short-term neonatal outcomes among pregnancies after 32 weeks gestation.